Insulin degludec/insulin aspart produces a dose‐proportional glucose‐lowering effect in subjects with type 1 diabetes mellitus

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|7|659-664

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.7, 2015-07, pp. : 659-664

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 636-644

John Wiley & Sons Inc

Access to resources Recommend Favorite

Insulin degludec in Type 1 diabetes

By Eligar Vinay S   Bain Stephen C  

Clinical Investigation, Vol. 3, Iss. 10, 2013-10 ,pp. : 943-950

Future Science

Access to resources Recommend Favorite

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

By  

PEDIATRIC DIABETES (ELECTRONIC), Vol. 16, Iss. 3, 2015-05 ,pp. : 164-176

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 350-362

John Wiley & Sons Inc

Access to resources Recommend Favorite